Assessing the Clinical Outcomes of a Novel Edof Intraocular Lens: a Functional Classification Approach

Background Functional assessment can help identify the true extended depth of focus intraocular lenses (EDOF IOLs) on the market. This study aimed to demonstrate the eligibility of the 877PEY ELON IOL (Medicontur Medical Engineering) as a suitable model for this category and to assess its efficacy in clinical settings. Methods In total, 38 patients (76 eyes) were enrolled in the study with bilateral implantation of the investigational IOL. For functional classification, a distance-corrected monocular defocus curve was taken 3 months postoperatively. At the 3- and 12-month follow-ups, manifest refraction, monocular and binocular distance, intermediate and near visual acuities, contrast sensitivity, and patient-reported outcomes were recorded. Results The defocus range (visual acuity [VA] ≤ 0.2 logMAR) on the distance-corrected monocular normalized defocus curve taken at 3 months was 1.7 D, which falls into the Partial Range of Field Extend (later referred to as PRoF-Ex) category, confirming expectations. The binocular depth of focus (VA ≤ 0.1 logMAR) spanned approximately 0.50 D to -1.50 D, and the functional visual acuity (VA ≤ 0.3 logMAR) spanned approximately 1.00 D to -2.50 D. Monocular CSV-1000 outcomes were above the population normal ranges. 90.9% of the patients were within ± 0.50 D, and 97.7% were within ± 1.00 D SEQ from the target refraction at the 3-month follow-ups. The outcomes of the VFQ-25 questionnaire demonstrated high scores, and the level of spectacle independence, similar to visual acuity, reflected a strong efficacy in distance and intermediate correction with functional near vision. In terms of photopic phenomena, 90% and 87.5% of patients experienced no-to-moderate rates of glare and halos, respectively. The posterior capsular opacification (PCO) rate was 7.89% at the 12-month follow-up. No adverse events were considered serious. Conclusions The 877PEY model demonstrated capability as a PRoF-Ex IOL with remarkable performance. It is safe to use and delivers a high degree of patient satisfaction.